Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

Zachary A. Cooper; Dennie T. Frederick; Zain Ahmed; Jennifer A. Wargo

doi:10.4161/onci.24320

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

Zachary A. Cooper, Dennie T. Frederick, Zain Ahmed, Jennifer A. Wargo

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.

Original language	English (US)
Article number	e24320
Journal	OncoImmunology
Volume	2
Issue number	5
DOIs	https://doi.org/10.4161/onci.24320
State	Published - May 2013

Keywords

BRAF
Checkpoint blockade
Immunotherapy
Melanoma
PDL1

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.24320

Cite this

@article{4517b2f191be45218a615b29a2bebf7f,

title = "Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma",

abstract = "The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.",

keywords = "BRAF, Checkpoint blockade, Immunotherapy, Melanoma, PDL1",

author = "Cooper, {Zachary A.} and Frederick, {Dennie T.} and Zain Ahmed and Wargo, {Jennifer A.}",

year = "2013",

month = may,

doi = "10.4161/onci.24320",

language = "English (US)",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "5",

}

TY - JOUR

T1 - Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

AU - Cooper, Zachary A.

AU - Frederick, Dennie T.

AU - Ahmed, Zain

AU - Wargo, Jennifer A.

PY - 2013/5

Y1 - 2013/5

N2 - The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.

AB - The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.

KW - BRAF

KW - Checkpoint blockade

KW - Immunotherapy

KW - Melanoma

KW - PDL1

UR - http://www.scopus.com/inward/record.url?scp=84886944616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886944616&partnerID=8YFLogxK

U2 - 10.4161/onci.24320

DO - 10.4161/onci.24320

M3 - Article

C2 - 23762807

AN - SCOPUS:84886944616

SN - 2162-4011

VL - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 5

M1 - e24320

ER -

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this